Physician profile
Jyoti Bhat
NPI 1588839500
$6,089.38
in general payments reported to CMS, 2019-2025
44 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $501 · 2021: $473 · 2022: $866 · 2023: $1,176 · 2024: $1,156 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646 · Education: $99.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,645.94 |
| Education | $99.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $857.62 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $544.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $374.65 | 2019-2025 | |
| Lilly USA, LLC | $371.83 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $359.95 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.38 | 2019-2024 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.65 | 2020-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $256.22 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Mannkind Corporation | $234.75 | 2019-2024 | Afrezza |
| Alexion Pharmaceuticals, INC. | $212.30 | 2021-2025 | Strensiq |
| Astellas Pharma US INC | $197.80 | 2024-2025 | Veozah |
| Corcept Therapeutics | $187.99 | 2022-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $178.08 | 2021-2025 | Gvoke Hypopen |
| Abbott Laboratories | $151.52 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $150.52 | 2019-2025 | Shingrix |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $145.50 | 2022-2025 | |
| Radius Health, INC. | $113.30 | 2022-2025 | Tymlos |
| Dexcom, INC. | $112.39 | 2022-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $84.09 | 2023-2025 | Yorvipath |
| Exact Sciences Corporation | $83.44 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $80.66 | 2022 | |
| Ibsa Pharma INC. | $69.39 | 2020-2023 | Tirosint, Licart |
| Irhythm Technologies, INC. | $66.22 | 2020 | |
| Averitas Pharma INC. | $60.15 | 2023-2025 | Qutenza |
| Madrigal Pharmaceuticals | $46.76 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $45.35 | 2020-2025 | Xyosted |
| Neurocrine Biosciences, INC. | $44.89 | 2025 | |
| Octapharma USA, INC. | $37.93 | 2019 | |
| Abbvie INC. | $35.00 | 2024 | |
| Fresenius Kabi USA, LLC | $34.82 | 2025 | |
| Insulet Corporation | $32.19 | 2021-2022 | |
| Beta Bionics, INC. | $31.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Globus Medical, INC. | $31.42 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $30.66 | 2019-2020 | |
| Esperion Therapeutics, INC. | $28.72 | 2025 | Nexletol |
| Kyowa Kirin, INC. | $28.31 | 2024 | Crysvita |
| Ars Pharmaceuticals Operations, INC. | $23.96 | 2025 | Neffy |
| Genentech USA, INC. | $22.60 | 2025 | Xolair |
| Grt US Holding, INC. | $19.38 | 2022 | |
| Organon LLC | $18.90 | 2025 | |
| Cequr Corporation | $17.82 | 2023 | Cequr Simplicity |
| Companion Medical, INC. | $15.86 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyoti Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.